Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Omeros Corporation currently has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 5 distinct examiners and 5 distinct art units. This distribution suggests a high degree of specialization for each application, with pending actions being handled by distinct examiners and within distinct art units.
KIFLE, BRUCK is the busiest examiner for this portfolio, currently managing 2 pending office actions. This concentration makes KIFLE, BRUCK the primary point of contact for these 2 pending office actions. The remaining pending actions are spread across the other 5 distinct examiners, indicating that while there is some concentration, the portfolio still requires individual examiner engagement for most of its matters.
The presence of 5 distinct art units for the 6 pending office actions indicates that the company's technology is being reviewed across several different specialized groups at the USPTO. With pending office actions in total, the prosecution team must manage distinct examiner relationships. The fact that the busiest examiner has a concentrated workload provides an opportunity for consistent strategy across those specific matters, while the rest of the portfolio remains decentralized.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 4 (67%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 2 | 79.3% | +15.8% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18656093 | Methods for Inhibiting Fibrosis in a Subject in Need Thereof | SKELDING, ZACHARY S | — |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | KIM, YUNSOO | 121d overdue |
| 18777239 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — |
| 18776612 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | — |
| 18656093 | Methods for Inhibiting Fibrosis in a Subject in Need Thereof | SKELDING, ZACHARY S | — |
| 18063018 | THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOF | CANELLA, KAREN A | — |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1644 | 1 |
| 1641 | 1 |
| 1643 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18777239 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | 1624 | §112 | Final Rejection | — | Pending | Jul 18, 2024 |
| 18776612 | MASP-2 INHIBITORS AND METHODS OF USE | KIFLE, BRUCK | 1624 | §112 | Final Rejection | — | Pending | Jul 18, 2024 |
| 18656093 | Methods for Inhibiting Fibrosis in a Subject in Need Thereof | SKELDING, ZACHARY S | 1644 | §102§103 | Non-Final OA | — | Pending | May 06, 2024 |
| 18176155 | HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS | KIM, YUNSOO | 1641 | §112 | Final Rejection | 121d overdue | Pending | Feb 28, 2023 |
| 18063018 | THERAPEUTIC ANTIBODIES THAT BIND TO THE SERINE PROTEASE DOMAIN OF MASP-2 AND USES THEREOF | CANELLA, KAREN A | 1643 | §112Other | Non-Final OA | — | Pending | Dec 07, 2022 |
| 17938421 | TARGETED CATALYTIC COMPLEMENT-ACTIVATING MOLECULES AND METHODS OF USE THEREOF | LI, RUIXIANG | 1674 | §102§112 | Non-Final OA | — | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOmeros Corporation has 6 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Bruck Kifle has the most, with 2 of Omeros Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
